Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

Journal of the National Cancer Institute

Volumn 94, Issue 7, 2002, Pages 504-513

  Yu, Xiaodan ^a   Guo, Z Sheng ^a   Marcu, Monica G ^a   Neckers, Len ^a   Nguyen, Dao M ^a   Chen, G Aaron ^a   Schrump, David S ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Surgery Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANSAMYCIN DERIVATIVE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; COUMARIN DERIVATIVE; CYCLIN A; CYCLIN E; DEPSIPEPTIDE; FR 901228; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE 1; MUTANT PROTEIN; NOVOBIOCIN; ONCOPROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P21; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; TRICHOSTATIN A;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG NON SMALL CELL CANCER; MODULATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

EID: 0037012344     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.7.504     Document Type: Article

References (52)

1. Histone acetylation and disease
2. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer
3. Histone acetylation and the cell-cycle in cancer
4. Role of histone acetylation in the assembly and modulation of chromatin structures
5. Histone methylation versus histone acetylation: New insights into epigenetic regulation
6. Participation of histones and histone-modifying enzymes in cell functions through alterations in chromatin structure
7. Transcriptional control at regulatory checkpoints by histone deacetylases: Molecular connections between cancer and chromatin
8. Histone acetylases and deacetylases in cell proliferation
9. Acetylation: A regulatory modification to rival phosphorylation?
10. Three proteins define a class of human histone deacetylases related to yeast Hda1p
11. Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras
12. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization
13. Histone acetylation and transcriptional regulatory mechanisms
14. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
15. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
16. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1
17. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors
18. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts
19. Histone deacetylase inhibitors as potential anti-skin cancer agents
20. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
21. Labelling DNA strands breaks with BrdUTP. Detection of apoptosis and cell proliferation
22. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins
23. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90
24. Trichostatin A modulates expression of p21waf1/cip1, Bcl-xL, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells
25. P21-dependent g(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228
26. Regulation of p53 stability and activity in response to genotoxic stress
27. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity
28. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
29. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway
30. Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation
31. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects
32. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells
33. Antitumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
34. Effect of trichostatin A on cell growth and expression of cell cycle- And apoptosis-related molecules in human gastric and oral carcinoma cell lines
35. Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines
36. Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells
37. Regulation of p53 stability
38. Regulation of p53 expression by the RAS-MAP kinase pathway
39. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity
40. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
41. v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells
42. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
43. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway
44. The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal
45. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism
46. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis
47. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity
48. The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase
49. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
50. Regulation of E2F1 activity by acetylation
51. Acetylation of HMG I(Y) by CBP turns off IFN β expression by disrupting the enhanceosome
52. Acetylation control of the retinoblastoma tumour-suppressor protein